strong increas guidanc product traction
continu provid book momentum
improv optun reimburs
taz get prioriti review es nda fl track
record enterpris deal pipelin increas mix creat
uncertainti time book lumpi
report strong wait
physician weigh allogen car-t result prescrib
consider ahead result
strong book ep quarter select pursu
shift away perpetu licens model unwind
review glide toward ep
analyst certif import disclosur see
trd move forefront pipelin runneth
updat strengthen clinic evid inclisiran
thought
takeaway meet manag reiter
strive data week juli look rapid movement
first glanc
phase result accordion downgrad
pivot escharex boost commerci profil today
 day offer detail commerci posit timelin
aaic afterthought takeaway expert call
high mark multitaa pancreat cancer
look ahead updat
weak pancreat data unwarr reiter
sale slightli ahead our/street estim ep ahead us/
street higher sale higher gross margin/bett sg leverag constant currenc sale growth line
think knee driver out-performance offset lower spine/cmf hip base
stabil manufactur suppli increas confid sale organ stabil
manag see increas momentum move forward goal grow within weight averag market growth
six month versu previous rosa placement far still modest earli stage
launch feedback posit manag note increas invest rosa commerci
organ guidanc increas low end sale ep manag also take advantag lower
expect tax rate reinvest commerci organ
top stori week earn season pick report result addit
senat financ commite pass bill would crack larg increas drug price cap senior medicar part
out-of-pocket spend shift catastroph drug risk health plan drug manufactur howev legisl
expect hit senat floor august recess
strong increas guidanc product traction continu provid book momentum
beat expect comfort move rev/ep guidanc midpoint higher compani also lift
book midpoint cite strong momentum core xt newer product launch past sever
quarter strateg platform combin sever product autonom pharmaci concept gain traction
sever partnership quarter management note backlog all-tim high grow faster revenu
contract involv multipl product continu impress us believ import rx management insid outsid
hospit increas continu exhibit well differenti product reiter outperform target
improv optun reimburs
announc revenu higher consensu estim driven improv reimburs
us one-tim benefit collect manag indic reimburs improv sustain howev
collect benefit futur period may margin compani achiev sever key mileston quarter
import view favor medicar reimburs rate first-lin gbm maintain outperform rate
revis price target vs primarili owe higher revenu futur period improv gross margin
year-end anticip updat optun launch time china mileston trigger event also continu expect
medicar reimburs histor claim note time amount payment remain uncertain
taz get prioriti review es nda fl track
tazemetostat nda epitheloid sarcoma indic grant six-month prioriti review januari
fda action date assign expect acceler approv on/around time given robust data rare
malign lack approv option taz develop much larger follicular lymphoma market opportun
continu progress second nda submiss r/r fl remain schedul believ share
outperform tazemetostat progress develop approach commerci earlier
record enterpris deal pipelin increas mix creat uncertainti time book lumpi
vocera beat estim guidanc cut disappoint investor despit growth enterpris deal
pipelin management cut guidanc midpoint cite delay enterpris deal convers although
pick vendor choic increment approval/paperwork step fulli convert book take longer
sinc deal usual cover entir hospit instead one two depart believ process could
elong caus pipelin convers choppi uncertainti around book time unnerv
investor believ compani product competit posit record enterpris pipelin reiter
outperform rate adjust target
report strong wait
report adj ep vs opco/street estim adj-result exclud
normal item oig/stock options/stock comp/etc larg beat vs model driven combin segment
vita margin notabl out-performance bp vs estim due soon-to-be-releas highli
benefici medicar final rule announc would wait re-visit ep guidanc previous
exclud potenti materi benefit ep estim rais
furthermor rais price target
physician weigh allogen car-t result prescrib survey
today commerci avail chimer antigen receptor cell car-t therapi offer lifelin heavili pretreat patient
suffer certain hematolog malign conduct blind physician survey ascertain prescrib
percept surround limit current approv car-t product therapeut potenti off-the-shelf
allogen altern nearli respond believ allogen car-t could overcom key limit autolog
car-t envis car-t deploy second third-lin set importantli prescrib indic
may will exchang perform efficaci safeti conveni consist could
deliv off-the-shelf product survey data reinforc confid allogen product could eventu
becom standard care certain aggress leukemia lymphoma myeloma believ result posit
ramif sever allogen car-t develop includ cll crsp amongst sever
consider ahead result
highlight sever key topic ahead result updat jakafi script suggest volum growth
y/i without price increas lead us sale estim vs consensu note
jakafi sale guidanc long-term guidanc fda approv jakafi acut
steroid-refractori graft vs host diseas agvhd launch updat posit result topic ruxolitinib vitiligo
fda grant btd pemigatinib cholangiocarcinoma cca regulatori file expect may hear
potenti tumor-agnost develop refocu capit alloc oper new cfo
updat model adjust revenu ep detail insid
sale touch our/consensu estim fx headwind higher
expect oper margin lag estim higher sg ep vs our/street
discret tax benefit reiter organ sale guidanc ep guidanc rang
organ growth led endoscopi ep structur heart peripher despit fda paclitaxel safeti notic
tavr manag note acur momentum initi lotu recept posit remain confid
acceler led new product rollout includ lotu watchman eluvia japan exalt single-us
duodenoscop among other one sell day y/i versu one less day
sale our/consensu est organ growth well guidanc
ep beat our/consensu beat pull-forward expect sale
key organ beat come across css sale guidanc reiter organ ep up
beat help de-risk full-year organ sale guidanc investor concern given
previou back-half load natur guidanc guid still conservat built-in around final codman integr step
on-going competit launch dural repair/advanc energi driver focu includ on-going new product launch
highlight new icp monitor realigned/expand ott salesforc codman synergies/int expans
strong book ep quarter select pursu deal strateg criteria
report revenu slightli model vs beat adj ep estim
came ahead guidanc book highlight strong mix contract
new custom management stress select pursu deal align strateg margin target
compani could impact long-term book addit management introduc transform offic initi
drive variou strateg object season help book remain sidelin believ
magnitud opportun market dramat decreas limit compani growth potenti
shift away perpetu licens model unwind client deal impact fy guidanc
nexgen june revenu adjust ep came expect vs
estim increas shift away perpetu licens revenu toward subscript one signific deal unwind
due oper financi issu client unrel nextgen impact guidanc management reduc current-
year revenue/adj ep outlook midpoint client issu reduc annual revenu
rest attribut shift toward subscript increas shift toward subscript help visibl
near-term impact number like meaning management expect operating-margin target like
get push year
review glide toward ep
alexion provid sales/earn updat investor busi updat oper
progress remain beat-and-rais cycl guidanc adjust upward top
bottom line ep guidanc high end rang rest creep closer specul
eventu reach ye commerci launch ultomiri continu stride expect convers outpac
manag goal base check physician recent perform anticip convers
expect help address perceiv threat soliri franchis biosimilar patent remain
drag share updat model stay bullish
trd move forefront pipelin runneth
webcast updat highlight progress beyond mdd deliv posit open-label
data archway trial bipolar depress bpd respons rate also present post-hoc analysi
suggest potenti efficaci treatment resist depress trd trd priorit leverag
potenti launch mdd trd also broaden pipelin addit compound show
initi activ essenti tremor et nmda posit alloster modul show accept safeti
toler profil discuss potenti develop autism spectrum disord schizophrenia adhd
neurodegen diseas ad pd hd potenti post encephalit cognit adjust model reflect today
updat drive new vs prior
updat strengthen clinic evid inclisiran
mdco report adj ep vs consensu estim provid busi updat
focus impend phase data readout inclisiran encourag posit feedback earli payer
discuss ahead pivot readout seventh clean idmc safeti updat
patient year inclisiran materi safeti issu recent aha public show impact access
inhibitor cv outcom posit extens trial interim result nation lipid associ nla meet
miami fl updat cash runway fund pre-commerci effort nda file
long-term extens studi updat model actual detail insid
thought
morn report stronger expect sale ep sale organ well
guidanc rang came our/consensu estim codman specialti surgic css
particular driver beat versu estim ortho/tissu ott also come slightli ahead
higher sale sg leverag adjust ep y/i our/consensu estim
reiter organ revenu growth guidanc rais adjust ep guidanc rang
posit time benefit impact manag take account guidanc
consensu midpoint guid manag also cautiou respect final
step codman integr on-going competit launch dural repair tissu ablat though
chang manag expect item overal solid quarter help de-risk full year sale
guidanc organ growth concern investor given previou back-half load natur
year
takeaway meet manag reiter outperform
tuesday met manag discuss recent progress upcom catalyst enrol phase genesi
trial stem cell mobil underway manag re-affirmed studi track deliv top-line result
genesi support strong clinic proof-of-concept suffici cash compani support oper
registr file see blrx share current trade near cash bargain investor near term readout
pancreat cancer aml could provid addit catalyst refin estim reflect
commerci launch account recent reverse-stock split reiter outperform
rate adjust pt
report result beat top- bottom-lin commentari pipelin prioriti exhibit revenu
reach time high y/i outpac consensu estim driven larg ms
tecfidera vs consensu estim spinraza disappoint
vs consensu estim due unfavor ex-u dynam spend lower expect
 sg vs consensu respect think aducanumab-rel expens
unwind faster expect management commentari suggest program also evalu despit one-
timer encourag beat financi disciplin detail insid
report adjust ep includ acq expens vs opco/street
estim compar street estim out-performance due lower-
than-expect risk-adjust payabl due gain recogn relat ribera salud due
oper overal result strong exchang perform remain stabl highlight increas retent
driven ribera gain oper out-performance rais ep guidanc vs prior guidanc
follow quarter tweak ep estim lastli
note wellcar remain track close
strive data week juli look rapid movement partner
recent manag ndr follow key takeaway strive part data expect week juli
ex-u partner rezafungin near term prioriti eu primari focu identif activ
isom influenza compound may boost potenc compar alreadi impress data present eccmid
april acknowledg cdtx need increment fund oper top-line phase rezafungin
treatment data increment optimist partner debt may address major
requir would look accumul share cdtx prior strive data investor will hold stock
first glanc
report adjust ep includ acq expens vs opco/street
compani note out-performance due risk adjust payabl benefit come
ahead expect due ribera salud addit note invest incom top
expect overal result solid sg bp estim offset slightli higher hbr vs
opco/street follow quarter rais ep guidanc vs prior guidanc
result solid continu expect mco impact challeng political/regulatori environ
reflect perform follow releas
phase result accordion downgrad perform
accord studi compar ntec accordion pill carbidopa/levodopa ap-cd/ld immedi releas
ir-cd/ld fail detect statist signific differ primari endpoint off-tim chang baselin
patient parkinson diseas pd top-lin result await detail believ failur major
setback ntec remov ap-cd/ld model therebi updat revenu earn estim ntec
besid pd ntec still addit opportun drug includ proprietari partnership novarti merck
uncertain read across ap-cd/ld ap applic differ diseas beyond pd
downgrad ntec perform outperform remov pt time
last week featur posit data two welcom washington develop defens new
abbrevi check mostli posit pace enrol data plu help industri press detail
feder judg rule favor trump administr expans short-term health plan neg
propon mhn hous vote repeal cadillac tax never took effect khn presid
trump name healthcar economist toma philipson act chair council econom advis npr biden
unveil expans plan creat public option medicar buy-in elimin cap tax credit khn
berni sander meanwhil intensifi call medicar khn introduc hospit
bailout plan prevent closur becker earn kick wednesday night calendar
announc receiv notif complet respons letter fda regard file
hetlioz treat jet lag disord manag relay notif indic defici
supplement nda snda preclud discuss label post-market requir indic howev
fda specifi defici note pdufa date set manag plan obtain
addit clarif fda shortli model less peak revenu jet lag leav
pivot escharex boost commerci profil today day offer detail commerci posit
timelin
mdwd disclos plan shift develop escharex formul potenti longer half-
life less skin irrit longer patent life kick phase ii studi expect interim result late
would use weak mdwd share respons delay time-to-market vs move
gen formul directli phase buy opportun net expect escharex formul enjoy
stronger commerci posit base dose closer daili administr competitor santyl vs everi four
hour escharex potenti reduc skin red associ gen escharex await
detail today day
fda issu complet respons letter applic nurtec sublingu formul
riluzol amyotroph later sclerosi al cite issu apotex activ pharmaceut ingredi api use
studi manag confirm issu specif one apotex manufactur riluzol lot use refer
drug nurtec determin bioequival potenti rout address could independ third parti
reliabl assess api batch anoth bioequival studi use fda exempt voucher grant apotex
specif riluzol lot estim theoret neg impact pt launch delay one year
neg impact nurtec get market
gilead recent disclos fairli uniqu deal galapago glpg manag chang left
investor cautious optimist yet also puzzl earli move new ceo daniel day start
stock sinc vs nbi index believ manag turnov prep d/commerci
growth /glpg deal savvi one keep develop cost inflamm portfolio
glpg constrain cost-shar vs previous increas pipelin depth breadth
keep sharehold exposur potenti expens pipelin failur cap celg etc provid
greater filgotinib econom believ best-in-class
aaic afterthought takeaway expert call
host ad expert call follow aaic annual meet prof marwan sabbagh md director cleveland
clinic lou ruvo center brain health prof martin farlow md professor emeritu depart neurolog
indiana univers discuss focus implic aducanumab failur potenti learn data
observ kol favor robust dataset strong efficaci signal despit
failur primari endpoint bace inhibitor challeng potenti much inhibit elenbecestat may offer
milder profil tau activ area antibodi small molecul irna novel approach includ target
microglia bryostatin insulin sensit inflamm infecti diseas view discuss posit
pipelin base elenbecestat comment
high mark multitaa pancreat cancer
saturday marker collabor baylor colleg medicin bcm present initi data on-going phase trial
investig multitaa pancreat adenocarcinoma pa earli result suggest infus multitaa may deepen
respons frontlin chemotherapi least slow tumor progress treatment well-toler clinic benefit
correl expans multitaa-specif t-cell patient receiv multitaa monotherapi achiev
object respons treatment led diseas stabil higher rate expect rel histor control
believ interim result support continu investig pa indic current repres upsid valuat
marker reiter outperform pt
launch mvasi biosimilar bevacizumab kanjinti biosimilar trastuzumab us pioneer entrant
two potenti multi-billion dollar biosimilar market believ favor time launch facilit
recent district court denial motion restrain order preliminari injunct opinion significantli de-
risk surpris launch therebi unlock potenti upsid sharehold sever biosimilar product
includ amgevita biosimilar adalimumab success penetr european market us biosimilar
market remain uncertain updat model script adjust yet conserv hold
factor revenu mvasi kanjinti us bullish thesi base stabl outlook
look ahead updat
look forward updat juli particular interest ingrezza script growth perceiv
weak refil led q/q growth despit record number new patient start manag commentari
ingrezza growth trajectori includ long-term potenti updat orilissa launch dynam endometriosi plan
uterin fibroid color commerci potenti launch prepar follow opicapon nda accept
pdufa pipelin updat includ next gener vmat inhibitor vy-aadc expect solid
result ingrezza base rel low expect compar audit script data exhibit updat model
reiter outperform rate pt
weak pancreat data unwarr reiter outperform
morn american associ cancer research highlight select data marker on-going
phase trial pancreat cancer press releas result slate present tomorrow saturday
confer immun cell therapi cancer san francisco believ today weak marker share
may stem lack object respons multitaa monotherapi cohort howev given poor prognosi
patient fail frontlin chemotherapi limit size cohort believ diseas stabil
better metric judg multitaa set encourag data cohort explor multitaa frontlin
chemotherapi includ one complet respons cr two partial respons refer trial lead
folfirinox approv soc cr rate median os month patient
multitaa administ month soc chemotherapi patient respond stabl diseas
addit respons durabl data expect present could includ spider plot show tumor size trajectori pre-
post-multitaa infus may help highlight activ attribut multitaa
healthcar provid manag
